Screen and Detection for Early Stage Breast Cancers May Prevent Invasive Disease
Screening for and treatment of ductal carcinoma in situ (DCIS) is found to prevent subsequent invasive cancer.
Screening for and treatment of ductal carcinoma in situ (DCIS) is found to prevent subsequent invasive cancer.
Ductal Carcinoma (DCIS) is more likely to become invasive in people over 60 years old.
Researchers estimate the 20-year breast cancer-specific death rate for women diagnosed with ductal carcinoma in situ to be 3.3%.
Women diagnosed with ductal carcinoma in situ have a 20-year breast cancer-specific death rate of 3.3%.
[OncoTargets and Therapy] This research examines the effect of radiotherapy on overall survival in women with locally excised ductal carcinoma in situ (DCIS).
Although not usually recommended for women with localized cancer undergoing breast-conserving surgery, axillary lymph node evaluation is performed frequently in women with ductal carcinoma in situ (DCIS) breast cancer.
A multigene test was validated as a predictor of risk of disease recurrence among women treated with breast-conserving surgery alone for ductal carcinoma in situ (DCIS), according to data from a large study.
A gel form of tamoxifen applied to the breasts of women with noninvasive breast cancer reduced the growth of cancer cells to the same degree as the drug taken in oral form but with fewer side effects.
A team of stakeholders has detailed research priorities necessary to address gaps in knowledge about early breast tumors in women.
In women with ductal carcinoma in situ (DCIS), breast-conserving treatment combined with radiotherapy reduces the risk for local recurrence (LR), a recent study indicates.